Proteogenomic Analysis of Responders Versus Nonresponders in a Phase 1 Trial of Th17-Inducing Dendritic Cell Vaccination for Advanced-Stage Ovarian Cancer
Abstract
We recently completed a phase I clinical trial of Th17-inducing dendritic cell (DC) vaccination for stage IIIC IV ovarian cancer patients. Of 18 evaluable patients, 39 percent remain recurrence-free with a median follow-up of 49.2 months post-enrollment, and overall survival was 55 percent. The DC vaccine trial revealed a clear dichotomy between those patients that suffered from early recurrent disease (within 12-18 months), and those that enjoyed prolonged recurrence-free survival (4-5 years), thus posing the question of whether we can identify biomarkers of response versus non-response. This proposal will use state-of-the-art proteogenomic approaches to identify candidate biomarkers of responsiveness to Th17-inducing DC vaccination. The goals are (i) to identify markers associated with clinical response, and (ii) to identify markers associated with immune response. We have collated clinical metadata and conducted detailed feasibility analysis on tumor samples preparatory to in depth proteogenomic analysis. We anticipate that studies will be completed on schedule in year 2.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2022
- Accession Number
- AD1191151
Entities
People
- Martin J. Cannon
Organizations
- University of Arkansas for Medical Sciences